Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

If the string of biotech IPO filings the Nasdaq saw on market close Friday says anything other than that the window for public fundraising remains wide open, it’s about the diversity of areas these aspiring public drugmakers operate in — from immuno-oncology and Alzheimer’s to diabetic complications and cardio indications.